| All pts | EST | New |
---|---|---|---|
n | 970 | 284 | 62 |
Age (years) | 58.0 (50.0; 68.0) | 59.0 (48.0, 67.0) | 58.0 (47.0, 70.0) |
Disease duration (years) | 8.0 (4.0, 14.0) | 9.00 (5.0, 14.0) | 4.00 (1.00, 9.00) |
Gender % female | 77.3 | 78.4 | 77.4 |
RF pos % | 69.3 (n = 894) | 68.0 (n = 264) | 54.8 (n = 59) |
ACPA pos % | 47.6 (n = 633) | 50.0 (n = 193) | 37.1 (n = 46) |
Duration of bDMARD treatment prior inclusion (years) | 1.99 (0.22, 5.18) | 3.22 (1.53, 6.02) | na |
DAS28 | 3.26 (2.24, 4.20) | 2.67 (1.99, 3.70) | 4.46 (3.77, 5.35) |
RADAI-5 | 3.2 (1.6, 4.8) | 2.6 (1.2, 4.4) | 4.4 (3.2, 6.2) |
HAQ-DI | 0.75 (0.25, 1.25) | 0.63 (0.13, 1.19) | 1.00 (0.63, 1.38) |
GC % | 35.9 | 25.0 | 66.1 |
csDMARD % | 64.6 | 56.0 | 83.9 |